NIH "Return-On-Investment" Policy To Be Ready By July 1
Executive Summary
The National Institutes of Health has begun to draft a policy to ensure a return-on-investment for taxpayer-funded research projects that ultimately generate over $500 mil. in U.S. sales per year.
You may also be interested in...
NIH Royalty Plan Due March 31 Under Wyden Amendment To Funding Bill
The National Institutes of Health would be directed to develop a plan to ensure a "reasonable rate of return" on taxpayer funded research under an amendment to the Senate Labor/HHS appropriations bill.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials